Weight Loss in Obese Kidney Disease Patients After Bariatric Surgery

It is expected to enroll 22 obese subjects with chronic kidney disease (decrease in glomerular filtration and/or albuminuria/proteinuria). After the inclusion in the study patients will remain for six months with a reduced calorie diet until the day of bariatric surgery. Time monitoring of the patient after surgery is 24 months.

Inclusion criteria

• Age 18-70 years (male or female).
• BMI >35 kg/m2 who meet the following criteria:

• GFR 30-60 ml/min and proteinuria>1g/24 hours despite receiving maximally tolerated doses of blocking the renin-angiotensin system.
• GFR >60 ml/min and proteinuria >(3.5) 2.5 g/24 hours despite receiving maximally tolerated doses of blocking the renin-angiotensin system.
• Patients with BMI> 40 kg/m2 with a GFR> 30 ml/min and proteinuria >(1) 0.5 g/24 hours despite receiving maximally tolerated doses of blocking the renin-angiotensin system.
• Patients who are able to understand the purpose and risks of the study, which has been fully informed and have finally given the written informed consent according to the ICH-GCP. Patients who can not read or write but who properly understand the verbal information provided by the investigator (or sub-investigator) the consent will be granted orally before their inclusion and an independent witness will signing the informed consent document.

Exclusion criteria

• Subjects who are participating or have participated in another clinical trial and/or who are taking or have taken an experimental drug (not registered) in the last 28 days.
• Patients with chronic renal replacement therapy (hemodialysis and/or peritoneal dialysis) and/or renal transplantation.
• Patients with poorly controlled blood pressure (SBP> 170 mmHg or DBP> 110 mmHg).
• Patients with a history of cardiovascular events (stroke, ischemic heart disease) in the past six months.
• Patients treated with steroids or other immunosuppressants.
• Patients with a history of renovascular disease, obstructive uropathy, autoimmune diseases, cancer, drug use.
• Patients who are pregnant or lactating.
• Patients who do not sign the informed consent.
• A slight chance of compliance with visits scheduled in the protocol.